Following the dose escalation phase, an expansion cohort for patients with advanced malignant melanoma will be initiated. Ethics Approval The study is approved by the Ethic Boards in Sweden and Denmark.
4 years ago
Clinical • P1 data • PK/PD data • IO biomarker
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
Following the dose escalation phase, an expansion cohort for patients with advanced malignant melanoma will be initiated. Ethics Approval The study is approved by the Ethic Boards in Sweden and Denmark.
4 years ago
Clinical • P1 data • PK/PD data • IO biomarker
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
The dosing of ATOR-1015 has been safe and well-tolerated up to 200 mg. Dose escalation continues and the current dose level under evaluation is 400 mg. Research Funding: Alligator Bioscience AB
over 4 years ago
Clinical • P1 data
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TNFRSF4 (TNF Receptor Superfamily Member 4)